Bellerophon Therapeutics (NASDAQ:BLPH) has submitted an Investigational New Drug (IND) application to the FDA seeking sign-off for an open-label study evaluating INOpulse inhaled nitric oxide therapy in COVID-19 patients who require supplemental oxygen.
Shares up 3% premarket on modest volume.
https://seekingalpha.com/news/3559304-bellerophon-files-ind-for-inopulse-for-covidminus-19-share-up-3-premarket
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.